Viewing Study NCT00240994

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:41 AM
Ignite Modification Date: 2026-06-02 @ 6:47 PM
Study NCT ID: NCT00240994
Status: COMPLETED
Last Update Posted: 2017-01-02
First Post: 2005-10-14
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Kidney Failure, Chronic View
None Kidney Transplantation View
None Immunosuppression View
Keywords:

Keywords

Keyword Brief Keyword Text View
None End stage renal disease View
None Kidney transplantation View
None Renal transplantation View
None Kidney failure View
None Pediatric renal transplant recipients View
None Alemtuzumab View
None Campath View
None Mycophenolate mofetil View
None MMF View
None CellCept View
None Tacrolimus View
None Prograf View
None Sirolimus View
None Rapamycin View